trial · primary record
Elranatamab (Elra)
Plasmablastic Lymphoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 17 |
| Primary completion | 2030-12-01 |
| Primary endpoint | Feasibility of giving Elra in consolidation after therapy of PBL |
| Registry ID | NCT07647432 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:36.530Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07647432
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.